ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/SA/5037-Kurralta-Park-Icon-Cancer-Centre-Adelaide
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
22
trial(s) found.
NCT06909825
Advanced
Phase 2
Recruiting
A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) (
FPI-2265-203
)
PARP inhibitor
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4509 - North Lakes - Icon Cancer Centre North Lakes
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06727565
Advanced
Phase 2
Recruiting
A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma (
VELOCITY-HNSCC
)
Carboplatin
Domvanalimab
Paclitaxel
Zimberelimab
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
platinum-based antineoplastic agent
taxane
Head and neck squamous cell carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06712355
Advanced
Phase 3
Recruiting
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer (
BNT327-03
)
anti-PD-L1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06712316
Advanced
Phase 2 / Phase 3
Recruiting
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer (
BNT327-06
)
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
2830 - Dubbo - Dubbo Base Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06588478
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
BTK inhibitor
Chronic lymphocytic leukaemia
Small Lymphocytic Lymphoma
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Perth Blood Institute
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
Breast cancer
NSW
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NA
4215 - Southport - Icon Cancer Centre Southport
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06238479
Advanced
Phase 1
Recruiting
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors (
EXCEED
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT05981703
Advanced
Phase 1
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors (
BGB-A317-26808-101
)
HPK1 inhibitor
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2228 - Miranda - Southside Cancer Care Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05868174
Advanced
Phase 1
Recruiting
A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors (
177Lu-TLX250-001
)
177Lu-anti-CA9-radioconjugate
DNA-dependent protein kinase inhibitor
Clear cell renal cell carcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05676931
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer (
EDGE-Lung
)
CD73 inhibitor
Docetaxel
Domvanalimab
Quemliclustat
Zimberelimab
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
cancer therapy
cancer therapy,CD73-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
taxane
Non-small cell lung cancer
NSW
2640 - Albury - Border Medical Oncology Research Unit
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (WITHDRAWN)
QLD
4217 - Benowa - Pindara Private Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05393791
Advanced
Phase 2
Recruiting
ANZadapt
: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05279300
Advanced
Phase 1
Recruiting
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas (
CS5001-101
)
anti-ROR1 antibody-drug conjugate
Lymphoma
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide (TERMINATED)
NCT04176198
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis (
BBI-TP-3654-102
)
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
Momelotinib
Ruxolitinib
cancer therapy
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
Myelofibrosis
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT04170283
Haem
Phase 3
Enrolling by invitation
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies (
BGB-3111-LTE1
)
BTK inhibitor
B-cell malignancy
NOT Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
ACT
2606 - Canberra - Paratus Clinical Research Woden
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Brisbane Clinic For Lymphoma, Myeloma And Leukaemia
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05712889
Advanced
Phase 1
Completed
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer (
VNC-236-101
)
small-molecule-drug-conjugate,alpha-V-beta-3-targeting
Cancer
NSW
2109 - North Ryde - Macquarie University Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT05654623
Advanced
Phase 3
Active not recruiting
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (
VERITAC-2
)
ER PROTAC degrader
selective estrogen receptor degrader
Breast cancer
NSW
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT05645692
Advanced
Phase 2
Not recruiting
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy (
BO44157
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
bispecific PD-1/LAG3 antibody
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05494762
Advanced
Phase 1
Terminated
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors (
BGB-A317-B167-101
)
anti-PD-1 monoclonal antibody
bispecific CEACAM5/4-1BB antibody
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT05327530
Advanced
Phase 2
Active not recruiting
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley) (
MS100070-0119
)
anti-PD-L1 monoclonal antibody
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3011 - Footscray - GenesisCare Western Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Tasman Oncology
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
NCT05200273
Advanced
Phase 1
Unknown
A Phase 1a, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 in Subjects With Advanced or Metastatic Solid Tumors (
AK114-102
)
anti-IL-1beta monoclonal antibody
Cancer
Solid tumour
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT03177239
Advanced
Phase 2
Status unknown
A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602). (
UNISoN
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Carcinoma
Chromophobe renal cell carcinoma
Clear cell renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2086 - Frenchs Forest - Northern Beaches Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (14)
Active not recruiting (2)
Enrolling by invitation (1)
Completed (1)
Not recruiting (1)
Terminated (1)
Unknown (1)
Status unknown (1)
Recruitment Country and State
SA (22)
NSW (17)
VIC (17)
QLD (13)
WA (7)
TAS (4)
NZ (2)
ACT (1)
Phase
Phase 1 (8)
Phase 1 / Phase 2 (1)
Phase 2 (8)
Phase 2 / Phase 3 (1)
Phase 3 (4)
Trial Type
Advanced (18)
Haem (3)
Curative (1)
Cancer Therapy Class
PD-1/PD-L1
45%
PD-1
36%
PD-L1
18%
TIGIT
14%
VEGFA
9%
BTK
9%
ER
9%
oestrogen axis
9%
PARP
5%
PSMA
5%
B7H3
5%
NECTIN4
5%
HPK1
5%
DNA-dependent protein kinase
5%
CD73
5%
AR
5%
CYP17A1
5%
androgen axis
5%
ROR1
5%
JAK1
5%
JAK2
5%
alpha-V-beta-3
5%
ER
5%
LAG3
5%
4-1BB
5%
CEACAM5
5%
Trop2
5%
IL-1beta
5%
CTLA4
5%
Facility
5037 - Kurralta Park - Icon Cancer Centre Adelaide (22)
2109 - North Ryde - Macquarie University Hospital (6)
3168 - Clayton - Monash Medical Centre (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
4102 - Woolloongabba - Princess Alexandra Hospital (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
3128 - Box Hill - Box Hill Hospital - Eastern Health (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
5042 - Bedford Park - Flinders Medical Centre (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (3)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
2217 - Kogarah - St George Hospital (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
7000 - Hobart - Royal Hobart Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
7000 - Hobart - ICON Cancer Care Hobart (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2640 - Albury - Albury Wodonga Regional Cancer Centre (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
4509 - North Lakes - Icon Cancer Centre North Lakes (1)
2500 - Wollongong - Cancer Care Wollongong (1)
2830 - Dubbo - Dubbo Base Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
6005 - West Perth - Perth Blood Institute (1)
3630 - Shepparton - Goulburn Valley Health (1)
4215 - Southport - Icon Cancer Centre Southport
2228 - Miranda - Southside Cancer Care Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
4217 - Benowa - Pindara Private Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3002 - East Melbourne - Epworth Freemasons (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2606 - Canberra - Paratus Clinical Research Woden (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
4120 - Greenslopes - Brisbane Clinic For Lymphoma, Myeloma And Leukaemia (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2170 - Liverpool - Liverpool Hospital (1)
3011 - Footscray - GenesisCare Western Cancer Centre (1)
4215 - Southport - Tasman Oncology (1)
2031 - Randwick - Prince of Wales Hospital (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Urogenital cancer
Lung cancer
Respiratory tract cancer
Thoracic cancer
Male genital cancers
Prostate cancer
Non-small cell lung cancer
Haematological malignancy
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Head and neck cancer
Head and neck squamous cell carcinoma
Carcinoma
Breast cancer
Clear cell renal cell carcinoma
Kidney cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
B-cell malignancy
Lymphoma
Bladder cancer
Cervical cancer
Gastroesophageal cancer
Gastrointestinal cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Ovarian cancer
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Viral-related cancer
Urothelial carcinoma
B-cell lymphoma
Chronic lymphocytic leukaemia
Leukaemia
Lymphoid leukaemia
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
Colorectal cancer
Endometrial cancer
Epithelial Ovarian Cancer
Gastric cancer
Hepatobiliary cancer
Hepatocellular carcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Lower gastrointestinal cancer
Melanoma
Ovarian adenocarcinoma
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Sarcoma
Breast adenocarcinoma
Oesophageal cancer
Renal pelvis cancer
Triple-negative breast cancer
Myelofibrosis
Myeloproliferative neoplasm
Chromophobe renal cell carcinoma
Non-clear cell renal cell carcinoma
Papillary renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy